Overview
Alomone Labs is pleased to offer the P2X Receptor Antibodies for Pain Research Explorer Kit (#AK-380). This Explorer Kit includes P2X receptor antibodies for pain research with their respective peptide control antigen. An ideal tool for screening purposes.
Compounds
Product Name | Cat # | Size |
---|---|---|
Anti-P2X2 Receptor Antibody |
APR-003 | 1 x 50 µl |
P2X2 Receptor Blocking Peptide |
BLP-PR003 | 1 x 40 µg |
Anti-P2X2 Receptor (extracellular) Antibody |
APR-025 | 1 x 50 µl |
P2X2 Receptor (extracellular) Blocking Peptide |
BLP-PR025 | 1 x 40 µg |
Anti-P2X3 Receptor Antibody |
APR-016 | 1 x 50 µl |
P2X3 Receptor Blocking Peptide |
BLP-PR016 | 1 x 40 µg |
Anti-P2X3 Receptor (extracellular) Antibody |
APR-026 | 1 x 50 µl |
P2X3 Receptor (extracellular) Blocking Peptide |
BLP-PR026 | 1 x 40 µg |
Anti-P2X4 Receptor Antibody |
APR-002 | 1 x 50 µl |
P2X4 Receptor Blocking Peptide |
BLP-PR002 | 1 x 40 µg |
Anti-P2X4 Receptor (extracellular) Antibody |
APR-024 | 1 x 50 µl |
P2X4 Receptor (extracellular) Blocking Peptide |
BLP-PR024 | 1 x 40 µg |
Anti-P2X7 Receptor Antibody |
APR-004 | 1 x 50 µl |
P2X7 Receptor Blocking Peptide |
BLP-PR004 | 1 x 40 µg |
Anti-P2X7 Receptor (extracellular) Antibody |
APR-008 | 1 x 50 µl |
P2X7 Receptor (extracellular) Blocking Peptide |
BLP-PR008 | 1 x 40 µg |
Scientific Background
P2X receptors comprise a family of seven members (P2X1-7) of extracellular ATP-gated cation channels. They are expressed in somatic and nervous tissues. These receptors have been implicated in a variety of neurological, inflammatory and cardiovascular diseases1.
P2X receptors consist of two transmembrane subunits with a large extracellular domain, which shows conserved cysteine residues in all members of the family. P2X3 is the focus of pain pathways research due to its selective expression in nociceptive neurons. Interestingly, expression of P2X3 is species specific. While the rat form seems to be sensory neuron specific, in mice and human there is a broader pattern of expression, with some evidence for expression in cardiac muscle and motor neurons.
Immunocytochemistry studies have indicated an upregulation of P2X3 receptors in both DRG and dorsal horn neurons following neuropathic injury. ATP and thus P2X receptors play a significant role in pain pathways. Intrathecal administration of a P2X agonist produces a dose-dependent thermal hyperalgesic response which is blocked by P2X antagonists. ATP agonists do not cause a similar response in P2X1 receptors, suggesting it is not involved in this effect. Animals injected with P2X agonists exhibit overt nociceptive behaviour such as hindpaw lifting and licking2.
P2X receptors have also been implicated as having a major role in visceral sensory function and have been put forward as potential therapeutic targets for visceral pain such as IBD and IBS. ATP released from epithelium lining cells upon distention of hollow organs acts on the P2X receptors which relay the information to the CNS and subsequently cause pain3.
- Hausmann, R. et al. (2015) Curr. Med. Chem. 22, 799.
- Ding, Y. et al. (2000) J. Auton. Nerv. Syst. 81, 289.
- Deiteren, A et al. (2015) PLoS ONE 10, e0123810.